A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM

← catalyst calendar

NCT05761301

Sponsored by Alnylam Pharmaceuticals (industry) · ALNY — their whole pipeline →.

Phase

Phase 1/2

Status

Terminated

Study type

Interventional

Design

Randomized · Triple · Treatment

Enrollment

49actual

Sites

Countries

Canada, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Why the sponsor stopped it

Business reasons (not safety related)

As filed on the registry record, in the sponsor's own words.

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-03-10

actual

When the study began enrolling

Primary completion

2025-04-03

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2025-04-03

actual

The whole study's end, after follow-up

First posted

2023-03-09

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2025-05-07

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Type 2 Diabetes Mellitus (T2DM)

Interventions

Drug: ALN-KHK
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Part A: Frequency of Adverse Events

measured Up to 9 Months

Part B: Frequency of Adverse Events

measured Up to 12 Months

Publications

PMID 41388232 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · ALNY's whole pipeline · Catalyst calendar · Every registered study · What changed